Skip to main content

Dr. Vicky Makker, MD

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
23
In the NPI registry since
2008
Medicare patients seen, 2024
137

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2003Medical school: University of Florida College of Medicine
  • 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    NY license 239045-1

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
137
Services billed
525
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes483122
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes4019
New patient office or other outpatient visit, 60-74 minutes1717

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Industry-funded research

Named as a principal investigator on 9 industry-funded studies in 2025, from 4 companies. The companies reported $2,278,129 in research payments for these studies, mostly to the institutions running them.

  • A Phase II Trial of Pembrolizumab plus Lenvatinib for the Treatment of Patients with Advanced Uterine Carcinosarcoma
    Merck Sharp & Dohme LLC
  • Phase 2 Multicenter Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd DS-8201a) for the Treatment of Selected HER2 Expressing Tumours (DESTINY-PanTumor02)
    AstraZeneca Pharmaceuticals LP
  • A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab-Deruxtecan Dato-DXd as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced Metastatic…
    AstraZeneca Pharmaceuticals LP
  • STUDY NAME#A Phase II Trial of Pembrolizumab plus Lenvatinib for the Treatment of Patients with Advanced Uterine and Ovarian Carcinosarcomas
    Merck Sharp & Dohme LLC
  • A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001
    Merck Sharp & Dohme LLC
  • A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient dMMR Advanced or Recurrent Endometrial Ca…
    Merck Sharp & Dohme LLC
  • A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Subjects with Advanced Endometrial Cancer
    Merck Sharp & Dohme LLC
  • A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
    Karyopharm Therapeutics Inc.
  • Study name not reported
    Organon Llc

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in New York

Sources

NPI registry (CMS NPPES, November 2026; record last updated June 16, 2010), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1972769800. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.